WIXOM, Mich.—Rockwell Medical has hired Annamaria T. Kausz, MD, MS, to replace Dr. Richard Yocum as Vice President of Drug Development and Medical Affairs.
Kausz will be responsible for leading the new drug application (NDA) submission for Rockwell's Soluble Ferric Pyrophosphate (SFP) upon completion of its on-going Phase III CRUISE studies, as well as overseeing all aspects of clinical research and development for SFP and new drug indications.
"We are very excited to have Dr. Kausz join Rockwell and lead our clinical development program. Her experience is ideal for us,” said Robert L. Chioini, Chairman, CEO and President of Rockwell. “Dr. Kausz was the medical/scientific lead on the NDA submission for Feraheme, AMAG's intravenous iron product that was FDA approved in 2009, as well as for the subsequent Canadian NDS and European MAA submissions. She has extensive experience in interfacing with regulatory agencies, both U.S. and ex-U.S. She has actively participated in partnership and in-licensing initiatives and has been instrumental in securing ex-U.S. partnerships. Dr. Kausz has extensive hands-on experience in all phases of the clinical development process and in providing clinical oversight across multiple therapeutic indications, both in adult and pediatric populations. Her knowledge and expertise will be a tremendous asset to our team as we prepare to submit our NDA to the FDA for SFP market approval."
